Going Beyond PD-L1 for Predictive Biomarkers in Lung Cancer
August 15th 2016Biomarkers, such as immune cell PD-L1 expression, mutational burden, and immune system activation should be investigated further to clarify the mechanisms behind response and nonresponse to immunotherapy in patients with lung cancer.
Read More
Paul A. Bunn Jr, MD, discussed how combining immunotherapy with chemotherapy, molecular therapy, or anti-angiogenic therapy has shown promising results in recent randomized trials of patients with lung cancer, although the combinations have yet to demonstrate clear superiority.
Read More
Alaskan Oncology Practices Operate by Remote
March 3rd 2016Obtaining quality cancer care in Alaska is often difficult and expensive owing to the sparse highway network and the scattered nature of the state’s population of 736,000 people, who are spread out over more than a half-million square miles.
Read More